Data from Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers
Masaaki Komatsu(University of Chicago), Masahiko Nishiyama(Hiroshima University), Yoshiki Kudo(Hiroshima University), Eiso Hiyama(Hiroshima University), Michitaka Ohwada(Jichi Medical University), Junzo Kigawa(Tottori University Hospital), Mayu Yunokawa(Japanese Foundation For Cancer Research), Mitsuaki Suzuki(Josai University), Keiji Tanimoto(Hiroshima University), Megu Ohtaki(Hiroshima University), Keiko Hiyama(Hiroshima University), Nobutaka Nagai(Hiroshima University), Keiko Otani(Hiroshima University)
Cited by 0
Related Papers
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Apparent Diffusion Coefficient of Human Brain Tumors at MR Imaging
|Radiology|2005|505